133910-00-6

Basic information

• Product Name: N-Trityl Losartan Carboxaldehyde
• Synonyms: 2-butyl-4-chloro-1-((2-(2-trityl-2H-tetrazol-5-yl)-[1,1-biphenyl]-4-yl)methyl)-1H-imidazole-5-carbaldehyde(WXG02231)
• CAS NO: 133910-00-6
• Molecular Formula: C₄₁H₃₅ClN₆O
• Molecular Weight: 663.2092
• Mol File: 133910-00-6.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-Trityl Losartan Carboxaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: N-Trityl Losartan Carboxaldehyde(133910-00-6)
• EPA Substance Registry System: N-Trityl Losartan Carboxaldehyde(133910-00-6)

Safety Data

• Hazardous Substances Data: 133910-00-6(Hazardous Substances Data)

Usage

Chemical Properties

White to Off-White Solid

Uses

An intermediate in the synthesis of the EXP 3174, a metabolite of Losartan.

Upstream product

• 124750-99-8 cozaar 
• 76-83-5 trityl chloride 
• 114798-36-6 EXP 3179 
• 171515-67-6 2-n-butyl-1-{[2'-(2-triphenylmethyl-2H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carbaldehyde 
• 21615-34-9 2-Methoxybenzoyl chloride 
• 579-75-9 2-Methoxybenzoic acid 
• 133909-97-4 N-(trityl)-5-[4?-(methyl)biphenyl-2-yl]-2H-tetrazole 
• 84392-32-5 4,4-dimethyl-2-(4'-methyl-biphenyl-2-yl)-4,5-dihydrooxazole 
• 74201-13-1 N-(2-hydroxy-1,1-dimethyl)-2-methoxybenzamide 
• 79047-41-9 2-n-butyl-4-chloro-5-hydroxymethylimidazole 
• 114772-53-1 2-Cyano-4'-methylbiphenyl 
• 57598-33-1 2-(2-methoxyphenyl)-4,4-dimethyl-2-oxazoline 
• 83857-96-9 2-n-butyl-4-chloro-1H-imidazol-5-carboxaldehyde 
• 133051-88-4 N-(triphenylmethyl)-5-<4'-(bromomethyl)biphenyl-2-yl>tetrazole 

Downstream Products

• 1370339-88-0 [3-(3,4-bis-benzyloxy-phenyl)propyl](2-n-butyl-5-chloro-3-[2'-(2-trityl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl)amine 
• 133909-99-6 2-n-butyl-4-chloro-1-[(2'-(2-triphenylmethyl-2H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl]-1H-imidazole-5-methanol 
• 124750-92-1 2-n-butyl-5-chloro-3-[2'-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazole-4-carboxylic acid 
• 114798-36-6 EXP 3179 
• 1370339-80-2 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazole-5-carbaldehyde oxime 
• 947330-97-4 C₂₄H₂₅ClN₆O₂ 
• 124750-13-6 2-butyl-4-chloro-1-<<2'-(1H-tetrazol-5-yl)biphenyl-4-yl>methyl>imidazole-5-carboxaldehyde benzenesulfonylhydrazone 

Relevant articles and documents

Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor-γ and angiotensin II type 1 receptor

Because of the complex biological networks, many pathologic disorders fail to be treated with a molecule directed towards a single target. Thus, combination therapies are often necessary, but they have many drawbacks. An alternative consists in building molecules intended to interact with multiple targets, called designed multiple ligands. We followed such a strategy in order to treat metabolic syndrome, by setting up molecules directed towards both type 1 angiotensin II (AT1) receptor and peroxisome proliferator-activated receptor-γ (PPAR-γ). For this purpose, many molecules were prepared by merging both pharmacophores following three different strategies. Their ability to activate PPAR-γ and to block AT1 receptors were evaluated in vitro. This strategy led to the preparation of many new PPAR-γ activating and AT1 blocking molecules. Among them, some exhibited both activities, highlighting the convenience of this approach.

PROCESS FOR PREPARING BIPHENYLTETRAZOLE COMPOUNDS

Method for the preparing biphenyltetrazole compounds which are angiotensin II receptor antagonists or which are useful intermediates to prepare angiotensin II receptor antagonists. An illustrative biphenyl tetrazole compound is 2-n-butyl-4-chloro-1-[(2'-(tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl]-1H-imi dazole-5-methanol, potassium salt.

Tetrazolylphenylboronic acid intermediates for the synthesis of AII receptor antagonists

Novel tetrazolylphenylboronic acids, methods for their preparation, and their use in the syntheses of angiotensin II receptor antagonists are disclosed.